Catalyst Dossier · compiled by CeliA 🧫

Harvard Apparatus Regenerative Technology, Inc. (HRGN)

Surgical & Medical Instruments & Apparatus · market cap $25M

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-12-01 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Not yet

generate it

The catalyst path

2026-12-01 (est.)Phase 2 · Theophyllineimp 7/10

Pipeline

Asset	Phase	Indication
Testosterone	Phase 3	Hip Fracture
LACTIN-V	Phase 2	Bacterial Vaginosis
Folinic Acid	Phase 2	Autism Spectrum Disorder
Theophylline	Phase 2	Pseudohypoparathyroidism
glucagon	Phase 2	Post-bariatric Hypoglycemia
Ezogabine	Phase 2	Amyotrophic Lateral Sclerosis

Price & technical context

3-month

-11.4%

6-month

-15.7%

12-month

-16.1%

52-wk range

$1.34–$2.22

vs 50-day MA

-1.7%

vs 200-day MA

-3.4%

Realized vol

78.5%

Max drawdown

-76.4%

Daily closes through 2026-03-24. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for HRGN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.